Department of Pharmacy, National Cancer Centre Singapore, Singapore, Singapore.
Int J Hematol. 2010 Jun;91(5):826-30. doi: 10.1007/s12185-010-0583-z. Epub 2010 May 13.
Rituximab (Mabthera) is currently approved for the treatment of multiple subtypes of CD20-expressing, B-cell, non-Hodgkin's lymphoma. This study aimed to investigate whether rapid infusion of rituximab over 90 min is feasible without compromising patient's safety, and to reduce resource utilization at a cancer center. This is a prospective and open label study. Lymphoma patients who have received one cycle of rituximab without experiencing grade 3 or 4 infusional reaction were eligible for the rapid infusion of rituximab. Rapid infusion rituximab is infused over 90 min, with 20% of the dose given over the first 30 min and the remaining 80% over 60 min. A total of 79 patients were recruited for this study with a total of 269 infusions administered. Sixty-nine patients (87.3%) received rituximab in combination with chemotherapy. Average number of rituximab infusions administered to patients was 3.4 cycles. Rapid rituximab infusion schedule was well tolerated without any grade 3/4 infusion-related adverse events observed. An average amount of time saved per patient was 10.2 h. Rapid infusion rituximab over 90 min was well tolerated by patients, and shortened infusions have resulted in substantial reduction of resource utilization.
利妥昔单抗（美罗华）目前被批准用于治疗多种表达 CD20 的 B 细胞非霍奇金淋巴瘤亚型。本研究旨在探讨在不影响患者安全性的情况下，90 分钟内快速输注利妥昔单抗是否可行，并降低癌症中心的资源利用。这是一项前瞻性、开放标签研究。已接受一个周期利妥昔单抗治疗且无 3 级或 4 级输注反应的淋巴瘤患者有资格接受利妥昔单抗快速输注。快速输注利妥昔单抗输注时间为 90 分钟，前 30 分钟给予剂量的 20%，剩余 80%在 60 分钟内输注。本研究共招募了 79 例患者，共进行了 269 次输注。69 例患者（87.3%）接受了利妥昔单抗联合化疗。患者平均接受利妥昔单抗输注 3.4 个周期。快速利妥昔单抗输注方案耐受性良好，未观察到 3/4 级与输注相关的不良事件。每位患者平均节省时间为 10.2 小时。90 分钟内快速输注利妥昔单抗可被患者耐受，并且缩短输注时间可显著减少资源利用。
